Teva Pharmaceuticals USA Inc. has recalled 12,044 bottles of Metformin hydrochloride Extended-Release Tablets, 1000 mg. The recall was issued because the medication was found to contain levels of N-Nitrosodimethylamine (NDMA) that exceed acceptable daily intake limits. NDMA is an impurity that is classified as a probable human carcinogen. Consumers should talk to their doctor or pharmacist before they stop taking the medication, as it is important to maintain control of blood sugar levels. No injuries or illnesses have been reported to date.
The medication contains excessive levels of NDMA, an impurity that may increase the risk of cancer with long-term exposure. While NDMA is a common substance found in water and foods, the levels detected in these tablets exceed the safety thresholds established by the FDA.
You have 2 options:
Recall #: D-0441-2023; Distributed by Actavis Pharma, Inc.; Manufactured by Actavis Laboratories FL, Inc.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.